

1 Comparative Performance of SARS-CoV-2 Detection Assays using Seven Different Primer/Probe Sets and  
2 One Assay Kit

3

4 Amanda M. Casto<sup>a,b\*#</sup>, Meei-Li Huang<sup>c\*</sup>, Arun Nalla<sup>c\*</sup>, Garrett Perchetti<sup>c</sup>, Reigran Sampoleo<sup>c</sup>, Lasata  
5 Shrestha<sup>c</sup>, Yulun Wei<sup>c</sup>, Haiying Zhu<sup>c</sup>, Alexander L. Greninger<sup>c</sup>, Keith R. Jerome<sup>b,c</sup>

6

7 <sup>a</sup>Department of Medicine, University of Washington, Seattle, WA

8 <sup>b</sup>Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA

9 <sup>c</sup>Department of Laboratory Medicine, University of Washington, Seattle, WA

10

11 Running Head: Comparative Performance of SARS-CoV-2 Detection Assays

12

13 \*Amanda M. Casto, Meei-Li Huang, and Arun Nalla contributed equally to this work. Author order is  
14 alphabetical by last name.

15 #Address correspondence to Amanda M. Casto, [amcasto@uw.edu](mailto:amcasto@uw.edu).

16

17 **Abstract**

18 More than 100,000 people worldwide are known to have been infected with SARS-CoV-2  
19 beginning in December 2019. The virus has now spread to over 93 countries including the United States,  
20 with the largest cluster of US cases to date in the Seattle metropolitan area in Washington. Given the  
21 rapid increase in the number of local cases, the availability of accurate, high-throughput SARS-CoV-2  
22 testing is vital to efforts to manage the current public health crisis. In the course of optimizing SARS-  
23 CoV-2 testing performed by the University of Washington Clinical Virology Lab (UW Virology Lab), we  
24 tested assays using seven different primer/probe sets and one assay kit. We found that the most

25 sensitive assays were those the used the E-gene primer/probe set described by Corman et al.  
26 (Eurosurveillance 25(3), 2020, <https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045>) and the N2  
27 set described by the CDC (Division of Viral Diseases, Centers for Disease Control and Prevention, 2020,  
28 <https://www.cdc.gov/coronavirus/2019-ncov/downloads/rt-pcr-panel-primer-probes.pdf>). All assays  
29 tested were found to be highly specific for SARS-CoV-2, with no cross-reactivity with other respiratory  
30 viruses observed in our analyses regardless of the primer/probe set or kit used. These results will  
31 provide invaluable information to other clinical laboratories who are actively developing SARS-CoV-2  
32 testing protocols at a time when increased testing capacity is urgently needed worldwide.

33

#### 34 **Background**

35 In late December 2019, a cluster of cases of pneumonia of unclear etiology was first noted in  
36 Wuhan City in the Hubei Province of China (1). The etiology of these pneumonia cases, a novel type of  
37 coronavirus, was identified on January 7, 2020 (1). This novel coronavirus has now been named severe  
38 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) while the disease it causes is known as  
39 coronavirus disease 2019 (COVID-19) (2).

40 To date, the epidemic has been largely concentrated in China, with a total of 80,695 known  
41 cases as of March 7, 2020 (3). However, cases outside of China were observed early in the epidemic with  
42 the first detected in Thailand on January 13 (4). Soon afterwards cases were also identified in other east  
43 Asian countries including Japan and South Korea (1), which now has the largest number of known cases  
44 outside of China with 7,134 as of March 7 (3).

45 The Centers for Disease Control and Prevention (CDC) confirmed the first case of COVID-19 in  
46 the United States on January 21. The infected person was a 35 year old man who had recently returned  
47 to his home in Snohomish County, Washington after travelling to Wuhan City (5). No additional cases of  
48 COVID-19 were identified in Washington State until February 28 when two new cases were confirmed,

49 one in Snohomish County and one in neighboring King County, where Seattle is located (6). Since  
50 February 28, the number of cases of COVID-19 in Washington has steadily increased and currently  
51 stands at 102 (7).

52 In response to the rapidly increasing number of confirmed and suspected cases of COVID-19 in  
53 the Seattle metropolitan area, the Clinical Virology Laboratory at the University of Washington (UW  
54 Virology Lab) has begun testing clinical specimens for SARS-CoV-2. Prior to and since making this testing  
55 service available, we have endeavored both to optimize the performance of our assay and to increase  
56 the rate at which we are able to test samples. We report here our observations comparing three  
57 different RNA extraction methods. We also compare the performance of SARS-CoV-2 detection assays  
58 using seven different primer/probe sets and one assay kit.

59

## 60 **Materials and Methods**

61

### 62 *Samples*

63

64 Three sets of samples were used in our analyses. First, we used a set of approximately 300  
65 clinical respiratory samples sent to the UW Virology Lab for respiratory virus testing. These samples  
66 were in the form of nasopharyngeal or oropharyngeal swabs in viral transport media and had not  
67 previously been tested for SARS-CoV-2. Secondly, we used a collection of nasal swabs in viral transport  
68 media that are used to validate all assays performed at the UW Virology Lab. This collection includes  
69 samples positive for: rhinovirus (3 samples within the set), influenza B (2), influenza A (2), parainfluenza  
70 virus 1 (1), parainfluenza virus 3 (2), parainfluenza virus 4 (1), adenovirus (2), metapneumovirus (1),  
71 bocavirus (2), respiratory syncytial virus (2), coronavirus (25). The coronaviruses included in the sample  
72 set are non-SARS-CoV-2 samples. Twenty-two negative samples are also included in this sample set.

73 Finally, we obtained a set of 10 samples confirmed to be positive for SARS-CoV-2 by the Washington  
74 State Department of Health (WSDOH) Public Health Laboratories. These samples were also all  
75 nasopharyngeal or oropharyngeal swabs immersed in viral transport media.

76

#### 77 *RNA Extraction*

78

79 RNA extraction from samples was performed using two different systems, the MagNA Pure LC  
80 2.0 and the MagNA Pure 96 (Roche Lifesciences). For both systems, RNA extraction was performed  
81 according to the manufacturer's instructions. For the MagNA Pure LC 2.0, 200  $\mu$ L of each sample was  
82 subjected to extraction with an elution volume of 200  $\mu$ L. For the MagNA Pure 96, 200  $\mu$ L of each  
83 sample was subjected to extraction with an elution volume of either 50 or 100  $\mu$ L. 5  $\mu$ L of RNA in elution  
84 buffer was used in each SARS-CoV-2 detection assay.

85

#### 86 *SARS-CoV-2 Detection Assays*

87

88 We used a total of 7 different primer/probe sets in our SARS-CoV-2 detection assays. The  
89 University of Washington (UW) RdRp primer/probe set was designed by the UW Virology Lab. Three  
90 additional primer/probe sets were designed as described in Corman et al. (8); these will be referred to  
91 as the Corman N-gene, RdRp, and E-gene primer/probe sets. The Centers for Disease Control (CDC) N1,  
92 N2, and N3 sets were developed by the CDC and have been published on the CDC website (9).

93 For all of the above primer/probe sets, real-time RT-PCR assays were performed using the  
94 AgPath-ID One Step RT-PCR kit (Life Technologies). 25  $\mu$ L of reaction mix consists of 2x RT-PCR buffer,  
95 25x enzyme mix, primers/probes, and 5  $\mu$ L of extracted nucleic acid. Primer/probe concentrations were  
96 as recommended in Corman et al (8) and by a CDC recommended protocol (10). RT-PCR was performed

97 on an ABI 7500 real-time PCR system (Applied Biosystems) with cycle parameters: 10 minutes at 48 °C  
98 for reverse transcription, 10 minutes inactivation at 95 °C followed by 40 cycles of 15 seconds at 95 °C  
99 and 45 seconds at 60 °C.

100 We also tested samples for SARS-CoV-2 using the BGI RT-PCR detection kit (BGI). These assays  
101 were conducted according to the kit manufacturer's instructions.

102 A negative (human specimen control) was included in every RNA extraction procedure and non-  
103 template (water) control was included in every RT-PCR run. An internal control amplification was  
104 performed to monitor the extraction and RT-PCR quality.

105

## 106 **Results**

107

108 *Assays using UW RdRp and Corman N-gene primer/probe sets found to have LODs of 1:2x10<sup>3</sup>*

109

110 The first two primer/probes sets that we evaluated were the UW RdRp and the Corman N-gene  
111 sets. We tested the sensitivity of assays using these primer/probe sets by examining approximately 300  
112 clinical samples of unknown SARS-CoV-2 status. RNA was extracted for these assays using two different  
113 systems. The first was the MagNA Pure LC (LC) system, which is able to process 32 samples at a time and  
114 elutes RNA into 200 µL of buffer. The second was the MagNA Pure 96 (MP96) system, which is able to  
115 process 96 samples at a time and elutes RNA into 100 µL of buffer. One sample out of the 300 was  
116 positive for SARS-CoV-2. The positive result was consistent regardless of which of the two RNA  
117 extraction methods and which of the two primer/probe sets was used.

118 We then determined the limit of detection (LOD) of assays using the UW RdRp and Corman N-  
119 gene primer/probe sets when run on dilutions of the one positive clinical sample. For both RNA  
120 extraction techniques and both primer/probe sets, the LOD was found to be 1:2x10<sup>3</sup> (for each

121 combination of RNA extraction method and primer/probe set, twenty out of twenty replicate assays  
122 were positive for SARS-CoV-2 when the positive clinical sample was diluted to 1:2x10<sup>3</sup>). Finally, we  
123 tested the specificity of assays using both primer/probe sets by running them on a collection of samples  
124 that are positive for respiratory viruses other than SARS-CoV-2. Assays using both sets were found to be  
125 100% specific with no false positives noted in this analysis.

126

127 *Assays using the Corman RdRp and E-gene sets found to have LODs of 1:2x10<sup>4</sup>*

128

129 We next tested assays using the Corman RdRp and Corman E-gene primer/probe sets. We again  
130 used two RNA extraction methods. The LC extraction method was performed using the same protocol as  
131 before. However, for the MP96 method, we eluted RNA into 50 µL of buffer instead of 100 µL of buffer  
132 to determine whether this would increase the sensitivity of SARS-CoV-2 detection assays. We ran assays  
133 using both the Corman RdRp and the Corman E-gene primer/probe sets coupled with both RNA  
134 extraction methods on 10 samples confirmed by the WSDOH Public Health Laboratories to be positive  
135 for SARS-CoV-2. The results of these tests are shown in Table 1. There was one sample that was positive  
136 for assays using the E-gene set when the MP96 system was used but not when the LC system was used  
137 and two samples that were positive for assays using the RdRp set when the MP96 system was used but  
138 not when the LC system was used. Based on these results, we subsequently used the MP96 RNA  
139 extraction system with RNA eluted into 50 µL of buffer for all analyses.

140 To assess the sensitivity of assays using the Corman RdRp and E-gene primer/probe sets, we ran  
141 them on dilutions of the positive UW Virology clinical sample. The LOD was found to be 1:2x10<sup>4</sup> for both  
142 (again 20 replicate assays for each primer/probe set were performed and all 20 were positive). We also  
143 tested the specificities of assays using these sets by running them on our collection of samples positive

144 for various respiratory viruses. Like assays using the UW RdRp and the Corman N-gene primers, those  
145 using the Corman RdRp and E-gene sets were 100% specific with no false positives noted.

146

147 *Assays using the CDC N1 and N2 primer/probe sets performed better those using the N3 set*

148

149           Given that assays using the Corman RdRp and E-gene primer/probe sets showed superior  
150 performance relative to those using the UW RdRp and Corman N-gene sets, we wanted to compare the  
151 former to assays using the primer/probe sets published by the CDC: CDC N1, CDC N2, and CDC N3. We  
152 ran assays using these three sets on the 10 positive samples obtained from the WSDOH Public Health  
153 Laboratories. The results of these analyses are shown in Table 2. All assays produced positive results for  
154 all samples, except for the assay using the CDC N3 primers/probe which produced a negative result for  
155 SC5784. The assay using the Corman RdRp set also produced a negative result for this sample. For the  
156 other nine samples, assays using the Corman RdRp set consistently produced the highest cycle times out  
157 of all the assays compared in Table 2 (CDC N1, CDC N2, CDC N3, Corman RdRp, and Corman E-gene)  
158 followed by assays using the Corman E-gene set.

159

160 *Assays using the CDC N2 and Corman E-gene primer/probe sets were more sensitive than those using the*  
161 *CDC N1 and Corman RDRP sets and the BGI kit*

162

163           Our final analysis was to test the sensitivity and specificity of assays using the CDC primer/probe  
164 sets and compare these to the sensitivity and specificity of assays using the Corman RdRp and E-gene  
165 sets. Because assays using the N3 set did not perform as well as those using the N1 and N2 sets, we did  
166 not include the latter set in this analysis. We did, however, include in this analysis an evaluation of the  
167 sensitivity and specificity of assays performed using a SARS-CoV-2 test kit from BGI. To directly compare

168 LODs between assays using the Corman RdRp and E-gene sets to those using the N1 and N2 sets and the  
169 BGI kit, we ran assays on dilutions ranging from 1:10<sup>5</sup> to 1:10<sup>7</sup> of the positive UW Virology clinical  
170 sample. We again ran twenty duplicate assays with each primer/probe set and with the BGI kit on each  
171 dilution. The results of the analysis are shown in Table 3. The least sensitive assays were the ones that  
172 used the Corman RdRp primer/probe set. At a dilution of 1:10<sup>5</sup>, only 17 out of the 20 assays that used  
173 this set were positive for SARS-CoV-2. The most sensitive assays used the CDC N2 and the Corman E-  
174 gene sets for which 18 and 17 replicate assays, respectively, were positive at a dilution of 1:10<sup>6</sup>.

175 The specificities assays using the CDC N1 and N2 primer/probe sets and the BGI kit were also  
176 tested using our panel of samples positive for various respiratory viruses. Assays using the N1 and N2  
177 sets and the BGI kit were found to be 100% specific.

178

## 179 **Conclusions**

180 Known cases of COVID-19 have now exceeded 105,000 worldwide. While cases in China appear  
181 to be leveling off with fewer new cases diagnosed each day, new case clusters are rapidly appearing in  
182 other nations across the world (3). In the coming days and weeks, many clinical laboratories will be  
183 developing their own SARS-CoV-2 testing protocols. Maximizing the sensitivity and specificity of these  
184 tests is critical to efforts around the world to minimize the impact of this epidemic on global health.

185 A number of different primer/probe sets for use in SARS-CoV-2 detection assays and SARS-CoV-  
186 2 testing kits have been developed and are now available. As we have demonstrated here, the  
187 performance characteristics of assays using these primer/probe sets and testing kits are variable. Of the  
188 seven different primer/probe sets and one testing kit that we evaluated, all were found to be highly  
189 specific with no false positive results observed when assays were run on samples positive for a number  
190 of other respiratory viruses. Variability was, however, observed in the sensitivities of these tests. We



191 found that assays using the CDC N2 and Corman E-gene primer/probe sets to be particularly sensitive.  
192 Assays using these sets were able to detect SARS-CoV-2 in ten out of ten known positive clinical samples.  
193 They were also able to reliably detect SARS-CoV-2 in a positive sample diluted down to 1:10<sup>6</sup>. In addition  
194 to our evaluation of different assays for SARS-CoV-2 detection, we also show that it is possible to  
195 significantly increase capacity for the RNA extraction step of SARS-CoV-2 testing without sacrificing  
196 sensitivity.

197 In summary, we report variable performance characteristics of assays using seven different  
198 primer/probe sets and one complete testing kit used for SARS-CoV-2 testing of clinical samples. While  
199 assays using all sets were highly specific, some, such as those using the CDC N2 and the Corman E-gene  
200 sets, were found to be more sensitive than others. These findings will provide important insights on  
201 SARS-CoV-2 detection assay design to labs that are currently working to develop their own testing  
202 methods. Our results also emphasize the importance of on-going optimization of viral detection assays  
203 following the emergence of novel viral pathogens.

#### 204 **Funding**

205 This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID) (grant  
206 number 5T32AI118690-04 T32 Training Grant to AMC at the Fred Hutchinson Cancer Research Center).

#### 207 **Bibliography**

- 208 1. World Health Organization. 2020. Novel Coronavirus (2019-nCoV) Situation Report – 1. World  
209 Health Organization, Geneva, Switzerland.
- 210 2. Coronaviridae Study Group on the International Committee on Taxonomy of Viruses. 2020. The  
211 species *Severe acute respiratory syndrome-related coronavirus*: classifying 2019-nCoV and naming it  
212 SARS-CoV-2. *Nature Microbiology*. <https://doi.org/10.1038/s41564-020-0695-z>.

- 213 3. Dong e, Du H, Gardner L. 2020. An interactive web-based dashboard to track COVID-19 in real time.  
214 The Lancet Infectious Diseases. [https://doi.org/10.1016/S1473-3099\(20\)30120-1](https://doi.org/10.1016/S1473-3099(20)30120-1).
- 215 4. Okada P, Buathong R, Phuygun S, Thanadachakul T, Parnmen S, Wongboot W, Waicharoen S,  
216 Wacharapluesadee S, Uttayamakul S, Vachiraphan A, Chittaganpitch M, Mekha N, Janejai N,  
217 Iamsirithaworn S, Lee RT, Maurer-Stroh S. 2020. Early transmission patterns of coronavirus disease  
218 2019 (COVID-19) in travellers from Wuhan to Thailand, January 2020. Euro Surveillance 25(8).  
219 <https://doi.org/10.2807/1560-7917.ES.2020.25.8.2000097>.
- 220 5. Sun LH, Bernstein L. 2020. First U.S. case of potentially deadly Chinese coronavirus confirmed in  
221 Washington State. Washington Post.
- 222 6. Miller M, Chastaine D, Sullivan O. 2020. Coronavirus reaches Federal Way as USPS employee tests  
223 positive. Federal Way Mirror.
- 224 7. Fields A. 2020. Coronavirus deaths in Washington now at 16, with 102 confirmed cases. Seattle  
225 Times.
- 226 8. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, Bleicker T, Brünink S, Schneider  
227 J, Schmidt ML, Mulders DGJC, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski G,  
228 Romette J-L, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MPG, Drosten C. 2020.  
229 Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveillance 25(3).  
230 <https://www.doi.org/10.2807/1560-7917.ES.2020.25.3.2000045>.
- 231 9. Division of Viral Diseases. 2020. 2019-Novel Coronavirus (2019-nCoV) Real-time rRT-PCR Panel  
232 Primers and Probes. Centers for Disease Control and Prevention.  
233 <https://www.cdc.gov/coronavirus/2019-ncov/downloads/rt-pcr-panel-primer-probes.pdf>.

234 10. Division of Viral Diseases. 2020. Real-Time RT-PCR Panel for Detection of 2019-Novel Coronavirus:  
235 Instructions for Use. Centers for Disease Control and Prevention.  
236 <https://www.cdc.gov/coronavirus/2019-ncov/downloads/rt-pcr-panel-for-detection->  
237 [instructions.pdf](https://www.cdc.gov/coronavirus/2019-ncov/downloads/rt-pcr-panel-for-detection-instructions.pdf).

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

Sample IDs	Corman E-gene CTs <sup>1</sup>		Corman RdRp CTs <sup>2,62</sup>	
	LC <sup>2</sup>	MP96 <sup>3</sup>	LC	MP96
SC5777	27.2	24.9	29.1	29.0 <sup>263</sup>
SC5778	33.9	31.9	Negative	34.8 <sup>264</sup>
SC5779	37.7	34.7	Negative	36.5
SC5780	16.7	15.1	17.9	19.2 <sup>265</sup>
SC5781	17.2	16.2	18.6	20.2 <sup>266</sup>
SC5782	24.4	22.6	25.6	26.9
SC5783	18.4	16.9	19.6	20.8 <sup>267</sup>
SC5784	Negative	35.4	Negative	Negative <sup>268</sup>
SC5785	32.7	28.9	34.4	32.7
SC5786	27.6	25.6	28.1	29.4 <sup>269</sup>

270 **Table 1: Relative performance of SARS-CoV-2 detection assays using the Corman E-gene and RdRp**  
 271 **primer/probe sets and two different RNA extraction methods.**

272 <sup>1</sup>Cycle-times

273 <sup>2</sup>RNA extraction performed on the MagNA Pure LC system with RNA eluted into 200 µl of buffer.

274 <sup>3</sup>RNA extraction performed on the MagNA Pure 96 system with RNA eluted into 50 µl of buffer.

275

276

277

Sample IDs	CDC N1	CDC N2	CDC N3	Corman RdRp	Corman E-gene
SC5777	24.5	23.2	23.3	29.0	24.9
SC5778	30.2	30.6	30.1	34.8	31.9
SC5779	33.3	32.8	32.0	36.5	34.7
SC5780	14.6	13.7	13.9	19.2	15.1
SC5781	15.1	14.1	14.3	20.2	16.2
SC5782	21.8	20.9	21.0	26.9	22.6
SC5783	16.0	14.9	15.6	20.8	16.9
SC5784	36.0	35.6	Negative	Negative	35.4
SC5785	27.8	27.3	27.4	32.7	28.9
SC5786	23.9	24.0	24.3	29.4	25.6

278 **Table 2: Relative performance of SARS-CoV-2 detection assays using five different primer/probe sets.**

279

280

281

282

283

Corman E-gene							
Dilution	Sample ID	Replicates			% Positivity	CT <sup>1,2</sup> Mean	SD <sup>3</sup>
		Tested	Positive	Negative			
1:10 <sup>5</sup>	S5	20	20	0	100	33.7	1.13
1:10 <sup>6</sup>	S6	20	17	3	85	37.2	1.34
1:10 <sup>7</sup>	S7	20	3	17	15	37.9	0.10

Corman RdRp gene							
Dilution	Sample ID	Replicates			% Positivity	CT Mean	SD
		Tested	Positive	Negative			
1:10 <sup>5</sup>	S5	20	17	3	85	36.6	1.84
1:10 <sup>6</sup>	S6	20	2	18	10	35.8	1.79
1:10 <sup>7</sup>	S7	20	1	19	5	37.5	0.00

CDC N1							
Dilution	Sample ID	Replicates			% Positivity	CT Mean	SD
		Tested	Positive	Negative			
1:10 <sup>5</sup>	S5	20	20	0	100	33.7	1.45
1:10 <sup>6</sup>	S6	20	13	7	65	36.2	1.41
1:10 <sup>7</sup>	S7	20	2	18	10	36.2	0.55

CDC N2							
Dilution	Sample ID	Replicates			% Positivity	CT Mean	SD
		Tested	Positive	Negative			
1:10 <sup>5</sup>	S5	20	20	0	100	33.1	1.26
1:10 <sup>6</sup>	S6	20	18	2	90	36.8	1.35
1:10 <sup>7</sup>	S7	20	3	17	15	37.2	0.61

BGI Kit							
Dilution	Sample ID	Replicates			% Positivity	CT Mean	SD
		Tested	Positive	Negative			
1:10 <sup>5</sup>	S5	20	20	0	100	31.6	2.39
1:10 <sup>6</sup>	S6	20	10	10	50	34.7	2.06
1:10 <sup>7</sup>	S7	20	0	20	0	-	-

284 **Table 3: Relative sensitivities of SARS-CoV-2 detection assays using 4 different primer/probe sets and**

285 **the BGI testing kit.**

286 <sup>1</sup>Cycle-time

287 <sup>2</sup>Only positive results are included in calculation of mean CT

288 <sup>3</sup>Standard deviation